917 related articles for article (PubMed ID: 28947042)
1. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
2. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
3. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.
Raghu G
Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074545
[TBL] [Abstract][Full Text] [Related]
4. Evaluating new treatment options.
Nathan SD
Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.
Ahluwalia N; Shea BS; Tager AM
Am J Respir Crit Care Med; 2014 Oct; 190(8):867-78. PubMed ID: 25090037
[TBL] [Abstract][Full Text] [Related]
6. Update in diffuse parenchymal lung disease, 2013.
Rosas IO; Kaminski N
Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic pulmonary fibrosis: the turning point is now!
Funke M; Geiser T
Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targets and early stage clinical trials for pulmonary fibrosis.
Sato S; Yanagihara T; Kolb MRJ
Expert Opin Investig Drugs; 2019 Jan; 28(1):19-28. PubMed ID: 30513000
[TBL] [Abstract][Full Text] [Related]
9. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
George PM; Wells AU
Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
[TBL] [Abstract][Full Text] [Related]
10. Current approaches to the management of idiopathic pulmonary fibrosis.
Raghu G; Richeldi L
Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
Sathiyamoorthy G; Sehgal S; Ashton RW
South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
Fukihara J; Kondoh Y
Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
[TBL] [Abstract][Full Text] [Related]
13. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
Spagnolo P; Maher TM; Richeldi L
Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies.
Magnini D; Montemurro G; Iovene B; Tagliaboschi L; Gerardi RE; Lo Greco E; Bruni T; Fabbrizzi A; Lombardi F; Richeldi L
Respiration; 2017; 93(6):379-395. PubMed ID: 28472808
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic pulmonary fibrosis: pathogenesis and management.
Sgalla G; Iovene B; Calvello M; Ori M; Varone F; Richeldi L
Respir Res; 2018 Feb; 19(1):32. PubMed ID: 29471816
[TBL] [Abstract][Full Text] [Related]
18. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
19. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
20. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
Inchingolo R; Condoluci C; Smargiassi A; Mastrobattista A; Boccabella C; Comes A; Golfi N; Richeldi L
Expert Opin Pharmacother; 2017 Oct; 18(15):1583-1594. PubMed ID: 28933616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
